Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2011-03-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validating the Clinical Effect of a Knee Orthosis
NCT06655558
Geniculate Artery Embolization for the Treatment of Knee Osteoarthritis
NCT05386797
Knee Articular Cartilage Repair: Cartilage Autograft Implantation System Versus Conventional Microfracture
NCT01498029
Autologous Cartilage Implantation vs Arthroscopic Debridement
NCT02636881
Geniculate Artery Embolization for Knee Osteoarthritis
NCT03835988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The remaining capsule tissue not used for this study will be banked and made available to other researchers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
osteoarthritis, total knee arthroplasty
The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
No interventions assigned to this group
contracture post arthroplasty
A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Suspected neoplasia
* Suspected infection (which can cause arthrofibrosis)
* Hypertrophic scarring
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Ottawa Hospital Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Guy Trudel
Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Trudel, MD
Role: PRINCIPAL_INVESTIGATOR
University of Ottawa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ottawa Hospital
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010930-01H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.